



The Lupus Research Alliance unites the global lupus community in bold determination to free the world of lupus through the power of science.

We will transform the lives of people affected by lupus as we welcome and embrace a new scientific era, pioneer innovation, push the frontiers of knowledge, enlist diverse new scientific talent, and lead the drive to new treatments, prevention and cure.

## ONE OF THE MOST TRUSTWORTHY HEALTH ORGANIZATIONS IN THE COUNTRY

For the second year in a row the Lupus Research Alliance (LRA) was named by *Consumer Reports* as **one of the best five health organizations** to donate to in 2018. This blue-chip recognition is based on ratings by independent watchdog groups like BBB Wise Giving Alliance and CharityWatch.

The LRA is second only to the National Institutes of Health (NIH) in funding lupus biomedical research. **We have invested more than \$200 million in lupus research programs** and delivered breakthroughs that are speeding up the development of new treatments and enabling scientists to investigate theories toward prevention and the ultimate goal – a cure.

## RESULTS DRIVEN RESEARCH

As the world's largest private funder of lupus research, the Lupus Research Alliance funded 15 scientists in 2018 to conduct promising investigations in three critical areas:

- 7 scientists received \$4.2 million in grants through our two-year Target Identification in Lupus grant program. Supporting highly meritorious research, this program aims to discover molecular pathways and therapeutic targets that will lead to new treatments.
- Our Novel Research Grant Program awarded \$1.8 million for 6 high-risk, high-reward, original research projects relevant to basic, translational, and clinical investigations in lupus.
- The Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity challenged 2 extraordinary scientists to pursue innovative, hypothesis- or discovery-driven projects with \$1 million in grants. Dr. Vijay Kuchroo is studying ways to harness regulatory T and B cells as a new approach to lupus treatment. Dr. Nir Hacohen is seeking better ways to treat lupus kidney disease.

Lupus Research Alliance's affiliate Lupus Therapeutics continues to offer an innovative approach to bringing better treatments –faster– to people with lupus by conducting clinical trials at top academic medical centers in North America through the Lupus Clinical Investigators Network (LuCIN).

### BOARD OF DIRECTORS


Richard K. DeScherer  
*Co-Chairman*  
Ira Akselrad  
*Co-Chairman*  
Brenda Blackmon  
Neil J. Burmeister  
Jerome A. Chazen  
Thomas Daniel, M.D.  
Jennie L. DeScherer  
Sir Marc Feldmann FRS  
Joe Germanotta  
Daniel M. LaVecchia  
Louis Lucido  
Joseph Mauriello  
*Treasurer*  
Molly McCabe  
Nadeem Meghji  
William J. Mulvihill  
Robert W. Pittman  
Robert J. Ravitz  
*Secretary*  
Carol Weisman  
Keith C. Wold  
William J. Wolfe  
Spencer Zwick

### OFFICERS

Kenneth M. Farber  
*President & CEO*  
Debra Rose  
*Chief Finance & Administrative Officer*  
Andrea J. O'Neill  
*Executive Director*

### SCIENTIFIC ADVISORY BOARD

Mary K. Crow, M.D.  
*Co-Chair*  
Gary Koretzky, M.D., Ph.D.  
*Co-Chair*  
Mary Collins, Ph.D.  
Anthony J. Coyle, Ph.D.  
C. Garrison Fathman, M.D.  
Kenneth Kalunian, M.D.  
Brian Kotzin, M.D.  
Virginia Pascual, M.D.  
David S. Pisetsky, M.D., Ph.D.  
Jane Salmon, M.D.  
Benjamin D. Schwartz, M.D., Ph.D.  
Mark J. Shlomchik, M.D., Ph.D.  
George Tsokos, M.D.



## POWER IN NUMBERS

If there is one thing that the Lupus Research Alliance has learned, it's that there is power in numbers, and we need no greater proof than our Walk with Us to Cure Lupus program.

Walkers – passionate about ending lupus – may walk because a family member, friend or colleague has lupus. Or they may walk because they have lupus themselves. The important part is they decided to be part of the solution. People around the country were resolute in participating in the LRA walk program to ensure better treatments and eventually a cure become a reality for lupus patients around the world. Such passion has generated nearly \$3 million in 2018. Even more remarkable is the fact that since this grassroots fundraiser began, a cumulative total of nearly \$39 million has been raised for critical lupus initiatives from these supporters.

We extend our sincere gratitude and appreciation to our Board of Directors, who fund all our administration and fundraising expenses. Their ongoing generosity allows us to commit 100% of all other donations to support lupus research programs.

The following is an overview of the Lupus Research Alliance's income and expenditures for the fiscal year ended December 31, 2018.

### Revenue & Other Support:

Contributions	\$ 15,396,535
Other Support	\$ 3,616,243

**Total Revenue & Other Support: \$19,012,778**

### Program Expenditures:

Research	\$ 9,608,831
Scientific programs	\$ 7,064,789
Public policy	\$ 788,377

**Total Program Expenditures: \$17,461,997**


**Administration Expenditures: \$ 1,973,754 ★**

**Fundraising Expenditures: \$ 3,179,907 ★**

**End of Year Net Asset Balance: \$41,261,296**

\*The LRA's Supporting Services are covered by donations from its Board of Directors.

Because the LRA Board of Directors funds our administrative and fundraising costs, 100% of your contribution to the LRA goes directly to support lupus research programs.



The LRA contracts Lutz and Carr, CPA's as its independent auditor. A complete copy of the audited financial statements of the LRA for the year ended December 31, 2018, together with the independent auditor's report thereon, may be obtained through a written request to the LRA's national office and is also available on the LRA website; lupusresearch.org. The LRA is tax-exempt under 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible to the extent allowed by law.



275 Madison Ave, 10th Floor  
New York, New York 10016